Key Facts
- CAS
- 446262-90-4
- Molecular Weight (MW)
- ≈3647 g/mol
- Half-life
- ~6–8 days (albumin binding via DAC; human studies)
- Unit
- mcg
- Administration Route
- Subcutaneous (research contexts)
- Frequency
- —
- Last updated
- 2/17/2026
- Targets
- GHRH receptor
Overview
—
Protocol
- Dosage Range
- Not established for approved medical use
- Frequency
- —
- Cycle
- —
- Administration Route
- Subcutaneous (research contexts)
- Reconstitution Guide
- —
Science
Mechanism of Action
Stimulates pituitary GH release via cAMP, extended by DAC.
Targets
GHRH receptor
Studies
- — Journal/year not available
Benefits
Sustained GH elevationAnti-agingRecovery
Potential Side Effects
- Flushing
- Water retention
References
References coming soon.
Suggest a reference